Yu Na, Wei Ying, Zhao Zhenlong, Cao Shiliang, Wu Jie, Cai Wenjia, Zhao Hanxiao, Yu Ming'an
Department of Interventional Medicine, China-Japan Friendship Hospital, Beijing, China.
China-Japan Friendship Institute of Clinical Medical Sciences, Beijing, China.
Int J Hyperthermia. 2025 Dec;42(1):2555496. doi: 10.1080/02656736.2025.2555496. Epub 2025 Sep 7.
This study aimed to evaluate the efficacy and safety of US-guided thermal ablation (TA) for solitary papillary thyroid carcinoma (PTC) in elderly patients.
This retrospective study included 91 elderly patients with solitary PTC who were treated with TA. The primary outcome was disease progression. The secondary outcomes included the volume change of ablated tumors, the volume reduction rate (VRR), the rate of complete disappearance, and complications.
There were 73 T1a stage, 10 T1b stage and 8 T2 stage PTC patients older than 65 years old included in this study. During a median follow-up of 22.0 months, the overall disease progression rate was 2.2% (2/91). One patient developed a new tumor, and another developed lymph node metastasis (LNM). No patients were diagnosed with local recurrence, lymphatic/distant metastasis, or death due to PTC. At the longest follow-up, 72 months after TA, the median VRR was 100.0%, and 90.9% (10/11) of ablated tumors had been fully absorbed. Transient hoarseness occurred in two patients (2.2%).
TA is an effective and safe option for elderly patients with solitary PTC, providing a minimally invasive alternative for those who refuse surgery or active surveillance.
本研究旨在评估超声引导下热消融（TA）治疗老年孤立性甲状腺乳头状癌（PTC）的疗效和安全性。
本回顾性研究纳入了91例接受TA治疗的老年孤立性PTC患者。主要结局为疾病进展。次要结局包括消融肿瘤的体积变化、体积缩小率（VRR）、完全消失率和并发症。
本研究纳入了73例T1a期、10例T1b期和8例T2期年龄大于65岁的PTC患者。在中位随访22.0个月期间，总体疾病进展率为2.2%（2/91）。1例患者出现新肿瘤，另1例发生淋巴结转移（LNM）。无患者被诊断为局部复发、淋巴/远处转移或因PTC死亡。在最长随访期，TA后72个月，中位VRR为100.0%，90.9%（10/11）的消融肿瘤已完全吸收。2例患者（2.2%）出现短暂性声音嘶哑。
TA是老年孤立性PTC患者的一种有效且安全的选择，为那些拒绝手术或主动监测的患者提供了一种微创替代方案。
